
In the forensic laboratory, urine samples are tested for evidence of prior GHB use.
Photo Credit: University of Zurich
Scientific Frontline: Extended "At a Glance" Summary: GHB-Pentose Biomarker
The Core Concept: GHB-pentose is a novel biomarker, composed of gamma-hydroxybutyrate (GHB) and a sugar, that extends the detection window for GHB consumption. Unlike standard GHB, which rapidly exits the body, this compound remains detectable in urine for up to three days.
Key Distinction/Mechanism: While standard forensic analysis can only detect GHB for six hours in blood and 12 hours in urine, mass spectrometry testing for GHB-pentose extends this timeline significantly. Furthermore, because GHB-pentose forms only after direct ingestion, it differentiates administered drugs from naturally occurring, postmortem GHB release.
Origin/History: A research team at the University of Zurich, led by Andrea Steuer, initially identified the biomarker in 2021. Between 2024 and 2026, subsequent clinical studies successfully evaluated the biomarker using genuine forensic casework.
Major Frameworks/Components:
- Forensic toxicology testing: Utilizing advanced biomarker profiling to identify the presence of rapidly metabolizing compounds.
- Mass spectrometry: Employing independent analytical chemistry methods to detect minute levels of a substance below standard thresholds.
- Postmortem biochemistry analysis: Differentiating between endogenous compound generation after death and the metabolization of exogenous substances.








.jpg)









